FTO and acute myeloid leukemia: One limitation is that our conclusions regarding the phenotypic and molecular consequences of FTO-lncAML depletion arise from experiments performed in an AML cell line setting; helpful additional information might be gleaned from technically more challenging experiments in primary human AML cells using both in vitro and in vivo approaches.